In May 2021, Alzheimer Europe has added two new Phase II trials to its Clinical Trials Watch - an innovative online resource providing up-to-date accessible information on clinical trials currently recruiting participants in Europe. The service provides information on twelve Phase II and six Phase III clinical trials that are investigating drugs for the prevention and treatment of dementia and/or Alzheimer’s disease (AD). The two new trials from the company Alector are recruiting research participants in several European countries:
-
INFRONT-2: the purpose of this study is to evaluate the safety and efficacy of AL001 in people at risk or with frontotemporal dementia. All participants will receive an intravenous infusion of AL001 every four weeks.
-
INVOKE-2: the purpose of this study is to evaluate the safety and efficacy of AL002 in people with early AD. Research participants will receive either an intravenous injection of AL002 or placebo every four weeks.
Further information about the CTW is available on: http://www.alzheimer-europe.org/Research/Clinical-Trials-Watch
